Edition:
India

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

0.67USD
14 Aug 2020
Change (% chg)

$-0.03 (-4.45%)
Prev Close
$0.70
Open
$0.71
Day's High
$0.72
Day's Low
$0.66
Volume
184,775
Avg. Vol
544,758
52-wk High
$4.46
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Acorda Reports Second Quarter 2020 Financial Results
Wednesday, 5 Aug 2020 

Aug 4 (Reuters) - Acorda Therapeutics Inc ::ACORDA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.35.Q2 GAAP LOSS PER SHARE $0.37.Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.FOR FULL-YEAR 2020, ACORDA CONTINUES TO EXPECT AMPYRA NET REVENUE TO BE $85 - $110 MILLION.FOR FULL-YEAR 2020, ACORDA CONTINUES TO EXPECT OPERATING EXPENSES TO BE $170 - $180 MILLION.  Full Article

Acorda Therapeutics Files For Resale Of Up To 9.6 Mln Shares Of Common Stock
Thursday, 16 Jan 2020 

Jan 15 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 9.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Acorda Therapeutics Said That EC Has Granted Marketing Authorization For Inbrija 33 Mg Inhalation Powder, Hard Capsules
Tuesday, 24 Sep 2019 

Sept 24 (Reuters) - Acorda Therapeutics Inc ::ON SEPT 24,CO SAID THAT EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR INBRIJA 33 MG INHALATION POWDER, HARD CAPSULES.MARKETING AUTHORIZATION APPROVES INBRIJA FOR USE IN 28 COUNTRIES OF EUROPEAN UNION, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN.  Full Article

Acorda Therapeutics Reports Q4 Adj. EPS Of $0.45
Friday, 15 Feb 2019 

Feb 14 (Reuters) - Acorda Therapeutics Inc ::Q4 NON-GAAP EARNINGS PER SHARE $0.45.Q4 GAAP EARNINGS PER SHARE $0.20.Q4 REVENUE $64.2 MILLION VERSUS $167.2 MILLION.Q4 REVENUE ESTIMATE $48.1 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.60 -- REFINITIV IBES DATA.INBRIJA COMMERCIALLY AVAILABLE IN 1Q19.AMPYRA (DALFAMPRIDINE) 4Q18 NET REVENUE OF $64.2 MILLION.2018 YEAR-END CASH, CASH EQUIVALENTS AND INVESTMENTS OF $445 MILLION.WILL NO LONGER PROVIDE REVENUE GUIDANCE FOR AMPYRA.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $70-$80 MILLION.  Full Article

Acorda Provides 2018 Highlights And 2019 Guidance At J.P. Morgan Healthcare Conference
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES 2018 HIGHLIGHTS AND 2019 GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE.ACORDA THERAPEUTICS INC - INBRIJA EXPECTED TO BE AVAILABLE IN Q1 2019.ACORDA THERAPEUTICS INC - AMPYRA (DALFAMPRIDINE) FULL YEAR 2018 NET REVENUE GREATER THAN $430 MILLION (UNAUDITED).ACORDA THERAPEUTICS INC - 2018 YEAR-END CASH AND CASH EQUIVALENTS APPROXIMATELY $445 MILLION (UNAUDITED).ACORDA THERAPEUTICS INC - RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $70-$80 MILLION.  Full Article

BRIEF-Acorda Therapeutics Files For Resale Of Up To 8.7 Mln Shares Of Common Stock

* ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 8.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/3ic48dB) Further company coverage: